Search Results - "Ricklis, Rebecca M."

Structure-function analysis of the antioxidant properties of haptoglobin by Melamed-Frank, Meira, Lache, Orit, Enav, Benjamin I., Szafranek, Tal, Levy, Nina S., Ricklis, Rebecca M., Levy, Andrew P.

“…Haptoglobin serves as an antioxidant by virtue of its ability to prevent hemoglobin-driven oxidative tissue damage. It was recently demonstrated that an…”
Get full text

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models by Denmeade, Samuel R., Sokoll, Lori J., Dalrymple, Susan, Rosen, D. Marc, Gady, Alyssa M., Bruzek, Debra, Ricklis, Rebecca M., Isaacs, John T.

“…Background A detailed understanding is evolving as to how androgen receptor (AR) functions as a transcriptional regulator via its binding to androgen response…”
Get full text

Screening a combinatorial peptide library to develop a human glandular kallikrein 2–activated prodrug as targeted therapy for prostate cancer by Janssen, Samuel, Jakobsen, Carsten M, Rosen, D Marc, Ricklis, Rebecca M, Reineke, Ulrich, Christensen, Soeren B, Lilja, Hans, Denmeade, Samuel R

“…Objective: Prostate cancer cells secrete the unique protease human glandular kallikrein 2 (hK2) that represents a target for proteolytic activation of…”
Get full text

A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias by Karp, Judith E., Ricklis, Rebecca M., Balakrishnan, Kumudha, Briel, Janet, Greer, Jacqueline, Gore, Steven D., Smith, B. Douglas, McDevitt, Michael A., Carraway, Hetty, Levis, Mark J., Gandhi, Varsha

“…Clofarabine has shown impressive response rates in patients with acute leukemias. In vitro investigations with clofarabine in combination with cyclophosphamide…”
Get full text

Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide by Karp, Judith E., Flatten, Karen, Feldman, Eric J., Greer, Jacqueline M., Loegering, David A., Ricklis, Rebecca M., Morris, Lawrence E., Ritchie, Ellen, Smith, B. Douglas, Ironside, Valerie, Talbott, Timothy, Roboz, Gail, Le, Son B., Meng, Xue Wei, Schneider, Paula A., Dai, Nga T., Adjei, Alex A., Gore, Steven D., Levis, Mark J., Wright, John J., Garrett-Mayer, Elizabeth, Kaufmann, Scott H.

“…The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of…”
Get full text

Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias by Abd Elmoneim, Abeer, Gore, Lia, Ricklis, Rebecca M., Boklan, Jessica, Cooper, Todd, Narendran, Aru, Rolla, Katherine, Scott, Tammy, Arceci, Robert J.

“…Background By inhibiting DNA repair, clofarabine (CLO) may augment cyclophosphamide (CY)‐induced DNA damage and apoptosis. We performed a Phase I study for…”
Get full text

Comparative study of PSMA expression in the prostate of mouse, dog, monkey, and human by Aggarwal, Saurabh, Ricklis, Rebecca M., Williams, Simon A., Denmeade, Samuel R.

“…BACKGROUND Intraprostatic PSMA targeted prodrugs/protoxins are under development in our laboratory. Future toxicologic studies of these therapies require…”
Get full text

Phase 1 dose-escalation trial of clofarabine followed by escalating dose of fractionated cyclophosphamide in adults with relapsed or refractory acute leukaemias by Zeidan, Amer M., Ricklis, Rebecca M., Carraway, Hetty E., Yun, Hyun D., Greer, Jacqueline M., Smith, B. Douglas, Levis, Mark J., McDevitt, Michael A., Pratz, Keith W., Showel, Margaret M., Gladstone, Douglas E., Gore, Steven D., Karp, Judith E.

“…Summary The prognosis of patients with relapsed and refractory acute leukaemia (RRAL) is very poor. Forty patients with RRAL were enroled [28 acute myeloid…”
Get full text

A rapid and sensitive method for determination of veliparib (ABT-888), in human plasma, bone marrow cells and supernatant by using LC/MS/MS by Reinhardt, Sarah, Zhao, Ming, Mnatsakanyan, Aleksander, Xu, Linping, Ricklis, Rebecca M., Chen, Alice, Karp, Judith E., Rudek, Michelle A.

“…A rapid and sensitive method was developed and validated using a liquid chromatographic method with tandem mass spectrometry detection (LC/MS/MS) for…”
Get full text

Pharmacokinetics, biodistribution, and antitumor efficacy of a human glandular kallikrein 2 (hK2)-activated thapsigargin prodrug by Janssen, Samuel, Rosen, D. Marc, Ricklis, Rebecca M., Dionne, Craig A., Lilja, Hans, Christensen, Soeren B., Isaacs, John T., Denmeade, Samuel R.

“…BACKGROUND Prostate cancer cells secrete unique proteases such as prostate‐specific antigen (PSA) and human glandular kallikrein 2 (hK2) that represent targets…”
Get full text

Abstract 4539: Anti-leukemic activity of mitochondria-targeted asymmetrical 2,2′-binaphthoquinones by Ricklis, Rebecca M., Vuica-Ross, Milena, Brodsky, Robert A., Sausville, Edward, Dang, Chi V., Karp, Judith E., Emadi, Ashkan

“…Introduction: Binaphthoquinones are unique molecules consisting of two linked naphthoquinone units. By definition biquinones cause more effective oxidative…”
Get full text

Phase I Clinical-Laboratory Trial of Clofarabine (CLO) Followed by Cyclophosphamide (CY) for Adults with Refractory Acute Leukemias: Evidence for Enhanced DNA Damage by Karp, Judith E., Ricklis, Rebecca M., Greer, Jacqueline, Briel, Janet, Levis, Mark J.

“…CLO is a nucleoside analog with ribonucleotide reductase inhibitory activity. As such, CLO has the ability to impede repair of damaged DNA. We designed a Phase…”
Get full text

In Vivo Correlates of Response for Phase I Trial of Oral Tipifarnib (T) Combined with Oral Etoposide (E) for Adults Age ≥ 70 with Newly Diagnosed Acute Myelogenous Leukemia (AML) Who Are Not Candidates for Traditional Cytotoxic Chemotherapy (TCC) by Ricklis, Rebecca M., Karp, Judith E., Feldman, Eric J., Galkin, Suzanne, Greer, Jacqueline M., Ironside, Valerie, Mirjafary, Kim, Talbot, Timothy D., Morris, Lawrence E., Wright, John J., Kaufmann, Scott H.

“…T is a farnesyltransferase inhibitor with clinical activity in elderly adults with newly diagnosed AML who are not candidates for TCC. For adults age ≥ 65 with…”
Get full text